Filing search / Longboard Pharmaceuticals, Inc. / "Majority" / Page 2

8-K

EX-99.2

1rbt8jnvctbfsmw904hr

12 Mar 24

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

4:10pm

424B5

w60t8ad ov

4 Jan 24

Prospectus supplement for primary offering

4:48pm

424B5

qvwzjjdlr6

2 Jan 24

Prospectus supplement for primary offering

4:54pm

8-K

EX-99.2

q573vyq4gvm 5b

2 Jan 24

Regulation FD Disclosure

9:44am

8-K

EX-99.1

73fbt dngpx5

29 Nov 23

Regulation FD Disclosure

8:35am

8-K

EX-99.1

vayqr0ancm

11 Oct 23

Regulation FD Disclosure

9:26am

8-K

EX-3.1

iv6p yywu53xhiai

22 Sep 23

Amendments to Articles of Incorporation or Bylaws

4:21pm

8-K

EX-99.1

yriqa0p3tn8jgd8h7b

23 Aug 23

Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study

8:46am

424B5

bofzkaxy

4 Aug 23

Prospectus supplement for primary offering

4:20pm

8-K

EX-99.1

m9j40qcneo

5 Dec 22

Regulation FD Disclosure

8:45am

S-3

a27 ci69di

30 Sep 22

Shelf registration

4:11pm